Oppenheimer & Co’s Definium Therapeutics DFTX Stock Holding History

Oppenheimer & Co’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$211K	Buy	+4,490	New	+$111K	﹤0.01%	1642
2025 Q3	–	Sell	-98,336	Closed	-$638K	–	1708
2025 Q2	$638K	Buy	98,336 +27,221	+38%	+$179K	0.01%	1054
2025 Q1	$416K	Buy	71,115 +5,574	+9%	+$39.9K	0.01%	1143
2024 Q4	$456K	Buy	65,541 +13,160	+25%	+$90.5K	0.01%	1100
2024 Q3	$298K	Buy	+52,381	New	+$364K	﹤0.01%	1232
2022 Q3	–	Sell	-854	Closed	-$8K	–	1430
2022 Q2	$8K	Sell	854 -1	-0.1%	-$13	﹤0.01%	1399
2022 Q1	$14K	Buy	+855	New	+$14.8K	﹤0.01%	1459

Other funds holding DFTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Oppenheimer & Co's DFTX Position: Q2 2026 in Review

Oppenheimer & Co opened a new position in Definium Therapeutics (DFTX) in Q2 2026: 4,490 shares worth $211K. The stake represents ﹤0.01% of the portfolio and ranks #1642 among its holdings. This is a return to the name: Oppenheimer & Co previously reported a position in DFTX as recently as Q2 2025.

Oppenheimer & Co first reported a position in DFTX in Q1 2022 and has held it in 7 quarters since. The position peaked at $638K in Q2 2025. 362 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

Oppenheimer & Co held 4,490 shares of Definium Therapeutics worth $211K as of Q2 2026.
Definium Therapeutics was a new Oppenheimer & Co position in Q2 2026.
Definium Therapeutics made up ﹤0.01% of Oppenheimer & Co's portfolio in Q2 2026, its #1642 holding.
Oppenheimer & Co first reported a position in Definium Therapeutics in Q1 2022 and has held it in 7 quarters since.
Oppenheimer & Co's Definium Therapeutics position peaked at $638K in Q2 2025.
362 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Oppenheimer & Co's 13F filing for Q2 2026, filed 3 Aug 2026.